» Articles » PMID: 29410932

A Developmental History of the Positive and Negative Syndrome Scale (PANSS)

Overview
Date 2018 Feb 8
PMID 29410932
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Psychometric instruments are products of their time-Their designs and initial purposes are influenced and shaped by the contemporary treatment regimens, context, and cultural and conceptual biases of their developers. In this review article, the authors explore the history of the most influential schizophrenia research tools that have been created over the past several decades. The authors describe the scientific concepts, cultural influences, and challenges of past and present researchers as they strive to develop better assessment tools for schizophrenia. Starting with Moore's Scheme for the Quantitative Measurement of Abnormal Emotional Condition, developed in the early 1900s, and concluding with Kay, Fiszbein, and Opler's Positive and Negative Syndrome Scale, developed in the 80s, the authors describe several scales and illustrate how each scale led to and influenced the development of a later scale. The authors hope that a better understanding of schizophrenia assessment tool evolution and limitations will assist in the development of new instruments that better address the global needs for the evaluation, research, and treatment of psychosis.

Citing Articles

What autism features in first episode psychosis? Results from a 2-year follow-up study.

Pelizza L, Federico A, Leuci E, Quattrone E, Palmisano D, Pupo S Eur Arch Psychiatry Clin Neurosci. 2025; .

PMID: 40045056 DOI: 10.1007/s00406-025-01986-1.


Pharmacist-led Si-care (schizophrenia care) model to improve medication adherence and symptom management in schizophrenia.

Cahaya N, Kristina S, Widayanti A, Green J Explor Res Clin Soc Pharm. 2024; 16:100544.

PMID: 39687446 PMC: 11647222. DOI: 10.1016/j.rcsop.2024.100544.


Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia.

Javitt D Adv Neurobiol. 2024; 40:411-451.

PMID: 39562453 DOI: 10.1007/978-3-031-69491-2_15.


Introducing a new severity specifier for schizophrenia: conceptual framework and clinical implications.

Gadelha A, Biokino R, Lorencetti P, Crossley N, Bordini D, Massuda R Braz J Psychiatry. 2024; 46:e20243722.

PMID: 39305519 PMC: 11773320. DOI: 10.47626/1516-4446-2024-3722.


Magnetic resonance imaging-based machine learning classification of schizophrenia spectrum disorders: a meta-analysis.

Di Camillo F, Grimaldi D, Cattarinussi G, Di Giorgio A, Locatelli C, Khuntia A Psychiatry Clin Neurosci. 2024; 78(12):732-743.

PMID: 39290174 PMC: 11612547. DOI: 10.1111/pcn.13736.


References
1.
Ban T . Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2009; 3(4):495-500. PMC: 2655089. View

2.
GORHAM D, Overall J . Drug-action profiles based on an abbreviated psychiatric rating scale. J Nerv Ment Dis. 1960; 131:528-35. DOI: 10.1097/00005053-196012000-00007. View

3.
WITTENBORN J, HOLZBERG J . The generality of psychiatric syndromes. J Consult Psychol. 1951; 15(5):372-80. DOI: 10.1037/h0054115. View

4.
Kay S, Fiszbein A, Opler L . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261-76. DOI: 10.1093/schbul/13.2.261. View

5.
Lorr M, RUBINSTEIN E . Factors descriptive of psychiatric outpatients. J Abnorm Psychol. 1955; 51(3):514-22. DOI: 10.1037/h0041165. View